Crescent Biopharma to Present at June Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO), a clinical-stage biotechnology company focused on cancer therapies, will present at two June 2026 investor conferences.
Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8, with live webcasts and 90-day replays.
Details
News Market Reaction – CBIO
On Jun 3, the first trading day after this news, CBIO closed 5.73% above the previous close.
Data tracked by StockTitan Argus for the Jun 3 session.
Key Figures
- Jefferies fireside time
- 4:20 p.m. ET
- Jefferies Global Healthcare Conference on June 3, 2026
- Goldman Sachs fireside time
- 8:40 a.m. ET
- Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026
- Webcast replay period
- 90 days
- Replay of conference webcasts on Crescent’s investor website
Historical Context
-
ASCEND Phase 1/2 ASCO Trial-in-Progress poster for CR-001 bispecific.
-
Stock option inducement awards to five non-executive employees.
-
Management presentations at three May healthcare and oncology conferences.
-
Q1 2026 results and pipeline update with cash runway into 2028.
-
Inducement option grants for two non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:
- 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
- Goldman Sachs 47th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.